Midostaurin latest market price and drug cost per box reference

Midostaurin is an important targeted drug for FLT3 mutation-positive acute myeloid leukemia (AML) and some patients with advanced systemic mastocytosis. It has not yet been officially launched in China, which makes its access and cost the most practical issues of concern to patients. Since it cannot be purchased directly in domestic hospital pharmacies, many patients will obtain the drug through formal overseas medical channels, and the supply of different versions and countries will lead to large price differences. Overall, midostaurin is still a relatively high-priced anti-cancer targeted drug globally. Patients need to understand the cost and supply stability of different versions in advance before choosing.

According to the current situation in overseas markets, midostaurin’s original drug is available in European, Indian and Turkish versions. Among them, the European version is the most expensive and is usually at the upper limit of the cost range among all versions. The current reference price of overseas original drugs is approximately between 20,000 and 120,000 yuan. The specific cost will fluctuate depending on national policies, supply batches, and logistics models. If patients choose original drugs from European channels, the price will usually be higher, but they may be more favored by patients in terms of packaging, labeling and channel formality.

In the Indian market, midostaurin is not only available as the original drug, but also as a generic version produced by local pharmaceutical companies. Indian generic drugs have long been known globally for their high cost performance due to their low production costs. Their drug ingredients are consistent with the original drugs and are versions that comply with international drug production standards. The current reference price of printed generic midostaurin (25mg*28 tablets) is about 9,000 yuan, which is significantly lower than the original drug. For AML patients who require long-term medication, it can effectively reduce financial pressure. Many patients will also choose Indian generic drugs as one of their long-term treatment options under the guidance of professional institutions.

Regardless of whether they choose original drugs or generic drugs, patients should focus on the formality of the source of the drugs. In particular, overseas drug purchases must be through qualified channels to avoid purchasing counterfeit drugs or informal drugs that are circulated without permission. At the same time, the cost difference should not be the only basis. Patients should also make a comprehensive judgment based on their own condition, doctor's advice, length of treatment, and family economic status. Since midostaurin usually needs to be used continuously according to the course of treatment, and the long-term expenditure is large, it is recommended to make a decision after consulting professional doctors and reliable institutions to ensure the quality of the drug and the safety of treatment.

Reference materials:https://www.drugs.com/